An evaluation of once-daily applications of diflorasone diacetate in eczematous dermatoses.
The efficacy of once-daily applications of 0.05% diflorasone diacetate in a cream or ointment formulation was evaluated in a 3-week study of 301 patients with eczematous dermatoses. The lesions were classified by severity and included those of an acute, sub-acute or chronic nature. Clinical evaluations were based on overall lesion improvement and improvement in specific signs and symptoms. Over 80% of patients reported the therapy to be good or excellent. Sixteen patients reported side-effects consisting largely of transient burning and stinging.
D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000368:Aged; D001623:Betamethasone / Q000008:administration & dosage / Q000031:analogs & derivatives*; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D004485:Eczema / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged
D001623:Betamethasone; C014477:diflorasone